EGFR and non-small cell lung carcinoma: There is consistent evidence across a number of meta-analyses that female NSCLC patients usually have better outcomes in response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) than male patients, with regard to OS [36] and PFS [37, 38].